A clinical trial investigating the safety and effectiveness of tirzepatide taken once weekly compared to insulin taken once daily in people with type 2 diabetes and increased cardiovascular risk.

Study completed — 2023
HREC ethics approval number 2018.333

About this study

The primary purpose of the study aims to address the following questions:

  • Whether tirzepatide can help study participants with type 2 diabetes
  • The safety of tirzepatide and any side effects when taken
  • How much tirzepatide should be given to study participants
  • How tirzepatide compares to insulin glargine

Anticipated enrolment close date: November 2019

Contact us to find out more about this research study, quoting reference number 2018.333

Who can take part

You may be eligible to take part in this study if:

  • You have been diagnosed with type 2 diabetes
  • You are aged 18 years or over
  • Have known cardiovascular disease
  • Your blood glucose levels could be better
  • You do not currently administer your diabetes medication via an injection

What's involved

  • Blood and urine samples
  • ECGs
  • Height and weight
Person handling test tubes for research


All research in Australia involving human participants is reviewed by an independent group called a Human Research Ethics Committee (HREC). The ethical aspects of this research study have been approved by the Royal Melbourne Hospital HREC.

This study is being carried out according to the National Statement on Ethical Conduct in Human Research (2007). This statement protects the interests of people who agree to participate in human research studies.

The RMH Clinical Trials Centre
Clinical Trials Centre

The Clinical Trials Centre (CTC) is a dedicated, purpose-built space where we conduct clinical trials.

The CTC is located on Level 2 South. When you arrive, if you are unsure where to go, talk to one of our friendly volunteers or the information desk staff.

Related services